| Similar Articles |
|---|
 |
The Motley Fool
May 3, 2007
Billy Fisher |
Optimism for OSI With Tarceva sales growing across the board and the potential for new uses on the horizon, coupled with a shrewd divestiture of an unprofitable product, the general outlook for OSI appears to be quite favorable. Investors, take note.   |
The Motley Fool
May 5, 2005
Charly Travers |
OSI's Cancer Blockbuster Tarceva will turn OSI Pharmaceuticals into a leading biotech. |
The Motley Fool
October 29, 2007
Billy Fisher |
Tarceva Sales Thrive at OSI The pharmaceutical's net revenue jumps 77%. Amazingly enough, there's still room for further growth at OSI. Investors, take note. |
The Motley Fool
August 22, 2005
Rich Duprey |
Fuzzy Outlook for OSI-Eyetech Merger OSI Pharmaceuticals appears to have little to gain from its purchase of Eyetech. The situation does offer an eye-opening lesson on the risks inherent in investing in such one-trick ponies. |
The Motley Fool
April 26, 2004
Alyce Lomax |
Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug. |
The Motley Fool
August 1, 2007
Billy Fisher |
Overseas Growth Sparks OSI's Earnings OSI Pharmaceuticals continues to prosper, and it has Tarceva to thank. But what happens when Tarceva becomes obsolete around 2009? Investors, take note. |
The Motley Fool
May 25, 2005
Tom Taulli |
Genentech's Vision Thing Genentech has been on fire. Now the challenge will be to manage the growth. Investors, take note. |
The Motley Fool
August 10, 2005
Seth Jayson |
Cisco on the Go: Fool by Numbers The company released its fiscal 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
November 19, 2004
Charly Travers |
A New Drug for Lung Cancer Genentech and OSI's launch of Tarceva brings a new choice in the treatment of lung cancer. |
The Motley Fool
January 5, 2005
Charly Travers |
AstraZeneca's Lead Evaporates Pulling an application for Iressa from the EU makes the drug a has-been. |
The Motley Fool
January 18, 2006
Seth Jayson |
Yahoo! Lurches Across the Line: Fool by Numbers The company released fiscal 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
March 30, 2010
Brian Orelli |
Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers. |
The Motley Fool
May 28, 2009
Brian Orelli |
Make Money, Fight Disease: The ASCO Preview The big cancer meeting is upon us. |
The Motley Fool
January 22, 2010
Brian Orelli |
Pfizer's Great Data Won't Do Much The full data from a clinical trial testing Pfizer's Sutent in pancreatic cancer was truly amazing. Unfortunately, it's not going to do very much for the stock or Pfizer's bottom line. |
The Motley Fool
December 30, 2009
Brian Orelli |
Pfizer Pflubs -- You Expected Otherwise? Bad news, but rather expected. |
The Motley Fool
July 20, 2005
Stephen D. Simpson |
Two Ways to Play Roche Trying to track Roche is a pain, so investors might want to think about Genentech instead. |
The Motley Fool
February 1, 2006
Tim Beyers |
Google's 2005 Growth Story: Fool by Numbers The Internet giant released fourth-quarter and full-year fiscal 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
Registered Rep.
February 1, 2005
Bob Hirschfeld |
Healing Investments New lung cancer drugs mean good news in both the doctor's office and on Wall Street. |
The Motley Fool
December 20, 2004
Charly Travers |
More Trouble at Big Pharma AstraZeneca's lung cancer drug is not as effective as once hoped. |
The Motley Fool
July 16, 2007
Brian Lawler |
Slight Setback for ImClone ImClone announces a failed cancer study. Investors, take note. |
The Motley Fool
May 23, 2006
Jim Mueller |
Mentor's Flat Year: Fool by Numbers Mentor released fiscal year 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
March 2, 2006
Tim Beyers |
StarTek Caught Gazing in 2005: Fool by Numbers StarTek released fourth-quarter and full fiscal 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
February 3, 2006
Tim Beyers |
Intuitive Surgical's Healthy 2005: Fool by Numbers Intuitive Surgical released fourth-quarter and fiscal 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
January 25, 2006
John Reeves |
Colgate-Palmolive Brightens: Fool by Numbers The company released fiscal year 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
July 6, 2009
Brian Orelli |
Lilly Shows Us How It's Done The company announces that the Food and Drug Administration had expanded the approval of its cancer drug, Alimta, to include maintenance therapy for nonsquamous, non-small cell lung cancer. |
The Motley Fool
February 23, 2006
Andy Cross |
Growing Cash at Dollar Tree: Fool by Numbers The discount retailer released full-year 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
February 14, 2006
Andy Cross |
No Black Eye for Blackboard in 2005: Fool by Numbers Blackboard released 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
January 18, 2006
Seth Jayson |
Intel Irritates Investors: Fool by Numbers The chipmaker released fiscal year 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
March 6, 2006
Seth Jayson |
Eagle FY 2005 Feathers Nest: Fool by Numbers American Eagle Outfitters released fiscal year 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
April 17, 2007
Brian Lawler |
ImClone Loses an Indication ImClone's lead drug fails in a clinical trial. Investors, take note. |
The Motley Fool
January 24, 2006
Tim Beyers |
EMC + 2005 = Margins: Fool by Numbers The storage device maker released fourth-quarter and fiscal year 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
July 22, 2005
John Reeves |
Microsoft's Record 2005: Fool by Numbers FY2005 The company released fiscal year 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
February 23, 2006
Seth Jayson |
Genuine Parts, Bigger Whole: Fool by Numbers The company released fiscal year 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
March 7, 2006
Seth Jayson |
Jo-Ann's Full-Year Flop: Fool by Numbers The retailer released fiscal year 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
January 20, 2006
Seth Jayson |
eBay Expands: Fool by Numbers The online auction house released fiscal year 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
November 14, 2006
Anders Bylund |
Spectrum Brands' Droopy Year: Fool by Numbers The global consumer-products supplier released full-year 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
August 10, 2005
Seth Jayson |
Cisco's Q4: Fool by Numbers The company released fourth quarter earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... etc. |
The Motley Fool
October 11, 2005
Stephen D. Simpson |
Genentech Generates Profits Whether you call it a biotech or a pharmaceutical, there's no disputing that Genentech is raking in some big bucks. Trying to value this stock is no treat, but growth-oriented investors should still have much to look forward to over the years. |
The Motley Fool
March 16, 2007
Billy Fisher |
Challenge Awaits Biovail The company's popular Wellbutrin XL will be facing generic competition soon. Biovail is currently trading 36% below its 52-week high. |
The Motley Fool
February 7, 2006
Seth Jayson |
Coca-Cola's Record Year for Cash: Fool by Numbers Coca-Cola released fiscal 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
February 21, 2006
Seth Jayson |
Home Depot's Solid Year: Fool by Numbers The home improvement retailer released fiscal year 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
August 11, 2005
Tim Beyers |
1-800-Flowers Hoping To Bloom Again: Fool by Numbers The company released 2005 fiscal year earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... etc. |
The Motley Fool
May 18, 2010
Brian Orelli |
What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout. |
The Motley Fool
June 4, 2008
Brian Lawler |
Erbitux's Deceptively Disappointing Results Poorly received lead-drug data batters ImClone shares. |
The Motley Fool
December 29, 2006
Brian Lawler |
Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide. |
The Motley Fool
July 28, 2005
Tim Beyers |
Sun Slowly Rising in 2005: Fool by Numbers Sun Microsystems released its 2005 fiscal year earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
September 13, 2006
Anders Bylund |
Pall Won't Fall: Fool by Numbers The filtration specialist released full-year 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
The Motley Fool
February 24, 2006
Seth Jayson |
Gap's Not So Good: Fool by Numbers The clothing retailer released full-year 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
March 15, 2007 |
Aloha, Alloy: Fool by Numbers The marketing services provider released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
